The Norwegian cardiovascular biopharmaceutical company Seordus AS announced that the Japanese Patent Office has granted a patent for Japan covering Serodus' proprietary product SER100, an ORL-1 receptor agonist, which Serodus intends to develop for patients with isolated systolic hypertension.

"The grant of this Japanese patent for SER100 protects a key commercial asset of the Company, and follows previous grants in Australia, New Zealand, and the USA. In addition, Canada is pending and a decision to grant was recently issued in Europe."

The patent covers a wide range of peptides, including SER100, pharmaceutical compositions containing SER100, as well as methods of treating different aspects of cardiovascular disorders caused by elevated nociceptin levels.

"The grant of this Japanese patent for SER100 protects a key commercial asset of the Company, and follows previous grants in Australia, New Zealand, and the USA. In addition, Canada is pending and a decision to grant was recently issued in Europe." said Dr. Eva Steiness, M.D., Chief Executive Officer of Serodus. "We look forward to the development of SER100 and moving the compound directly into clinical Phase II development.The primary goal will be to demonstrate that the compound reduces elevated systolic blood pressure with only a minor effect on diastolic pressure under co-treatment with a thiazide. The potential market segment for this indication is increasing due to the ageing population."

Source:
Seordus AS